NOVOPHARM MOVING INTO U.S. PRIVATE LABEL BUSINESS WITH GRANUTEC ACQUISITION from Roussel Uclaf Holdings, Toronto-based Novopharm announced on May 25. Terms of the deal were not disclosed. Novopharm predicted that the acquisition would be completed by June 30. Granutec OTC private label sales are expected to reach $ 40 mil. in 1993, up approximately 25% from the $ 32 mil. in sales generated in 1992. Novopharm Chairman and CEO Leslie Dan said that Granutec's headquarters in Wilson, N.C. will "eventually" be converted into Novopharm's U.S. manufacturing base. Novopharm is the leading manufacturer of branded prescription generic drugs in Canada, and the lion's share of the products it sells in the U.S. currently are manufactured in Canada. The company also sells private label OTCs through its Vancouver-based Stanley Pharmaceuticals subsidiary to retail chains in Canada. Privately held Novopharm's sales are currently annualizing at $ 240 mil. (approximately $ 300 mil. [Canadian]). "Our future plans include building new manufacturing facilities in Wilson and enlarging our facilities in Largo, Fla.," Dan said. "This will result in more than [double] the production capacity of the facilities, increased local employment, as well as an expanded market for Novopharm." The company plans to use the new and expanded facilities to manufacture branded generics, private label OTCs and "innovative pharmaceuticals that are currently under development."
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Lawmakers should address FDA staff upheaval and help the agency “get back on track,” former agency Chief of Staff Elizabeth Jungman said, while CBER Director Vinay Prasad told staff he is asking ex-colleagues to return to the agency.
NRx Pharma is trying to capitalize on the headlines about a new US FDA hyper-fast review program, illustrating that the lack of details in the FDA’s announcement is an opening for sponsors to try to grab some attention.
A survey asks FDA staff to disclose whether DEI policies caused discrimination or resulted in disciplinary action against career employees over the past five years, but uses a web form that the general public also can access.
